Success Metrics

Clinical Success Rate
100.0%

Based on 19 completed trials

Completion Rate
100%(19/19)
Active Trials
4(14%)
Results Posted
42%(8 trials)

Phase Distribution

Ph phase_3
1
4%
Ph phase_1
7
25%
Ph phase_2
11
39%
Ph early_phase_1
1
4%
Ph not_applicable
7
25%

Phase Distribution

8

Early Stage

11

Mid Stage

1

Late Stage

Phase Distribution27 total trials
Early Phase 1First-in-human
1(3.7%)
Phase 1Safety & dosage
7(25.9%)
Phase 2Efficacy & side effects
11(40.7%)
Phase 3Large-scale testing
1(3.7%)
N/ANon-phased studies
7(25.9%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

95.0%

19 of 20 finished

Non-Completion Rate

5.0%

1 ended early

Currently Active

4

trials recruiting

Total Trials

28

all time

Status Distribution
Active(5)
Completed(19)
Terminated(1)
Other(3)

Detailed Status

Completed19
Recruiting4
unknown3
Not yet recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
28
Active
4
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (3.7%)
Phase 17 (25.9%)
Phase 211 (40.7%)
Phase 31 (3.7%)
N/A7 (25.9%)

Trials by Status

not_yet_recruiting14%
completed1968%
recruiting414%
unknown311%
withdrawn14%

Recent Activity

Clinical Trials (28)

Showing 20 of 28 trialsScroll for more
NCT06741566Early Phase 1

Pre-operative Intra-nasal Dexmedetomidine or Insulin for Prevention of Early Post-operative Cognitive Dysfunction in Patients Undergoing Elective Coronary Artery Bypass Graft.

Recruiting
NCT05062785Phase 1

Dose-Finding Study of Intranasal Insulin in Healthy Participants Insulin in Healthy Participants

Completed
NCT07252752Not Applicable

Dopamine and Insulin in Psychosis

Not Yet Recruiting
NCT04044534Phase 2

Intranasal Insulin for Posttraumatic Stress Disorder

Recruiting
NCT05748990Not Applicable

Does Abnormal Insulin Action in the Brain Underlie Cognitive and Metabolic Dysfunction in Schizophrenia

Recruiting
NCT03943537Phase 2

Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders

Completed
NCT00916201Phase 1

Evaluation Study of New Compounds With Potential Use in Schizophrenia

Withdrawn
NCT03637075Not Applicable

Raclopride-PET/MRT

Completed
NCT06072963Phase 2

COMMETS- Combination MCI Metabolic Syndrome

Recruiting
NCT06144255Phase 1

Dose-Dependent Effect of Intranasal Insulin in Humans Using Functional Magnetic Resonance Imaging (fMRI)

Completed
NCT05613491Not Applicable

Intranasal Insulin Improves Postoperative Neurocognitive Disorders in Elderly Patients

Unknown
NCT03929419Not Applicable

"Effect of Central Insulin Administration on Whole-body Insulin Sensitivity in Women"

Completed
NCT03182322Phase 2

PINIT Study: Primary Intranasal Insulin Trial

Completed
NCT02810392Phase 2

Intranasal Insulin and Post-stroke Cognition: A Pilot Study

Completed
NCT00336674Phase 2

Trial of Intranasal Insulin in Children and Young Adults at Risk of Type 1 Diabetes

Completed
NCT04154449

Effect of Intranasal Insulin on Postoperative Cognitive Dysfunction

Unknown
NCT02154477Phase 1

Effect of Intranasal Insulin on LH Concentrations in Man

Completed
NCT01206322Phase 2

Enhancement of Cerebral Vasoreactivity and Cognition by Intranasal Insulin in Type 2 Diabetes

Completed
NCT03632681Not Applicable

Effect of Intranasal Insulin on Cognitive Processes and Appetite

Completed
NCT01781234Phase 2

Efficacy Study of Intranasal Insulin to Treat Tobacco Abstinence Syndrome

Completed

Drug Details

Intervention Type
DRUG
Total Trials
28